| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TransMedics Group, Inc.$71.23
-0.96 (-1.33%)
F 17Pipeline Score MedTech · Commercial
Market Cap
2.38 B
EPS
5.03
P/E Ratio
15.82 $
Value Trade
80.37 M
SEC Financials
Q1 2026Dilution Risk
Revenue
173.93 M
R&D Expenses
24.88 M
Operating CF
24.53 M
Total Assets
1.43 B
Total Liabilities
940.81 M
Equity
494.01 M
D/E Ratio
12,345
11.69 %
Week
-38.08 %
1 Month
-47.58 %
3 Month
-44.13 %
6 Month
182.4 %
5 Year
240.42 %
All Time
Cash Data
Cash Position
461.74 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
455.66 K
52 Week Range
60.11 - 156
% held by Insiders
3.46 %
% held by Institutions
108.83 %
Enterprise Value
2.78 B
Total Shares
34.55 M
Short %
24.46 %
Float Shares
32.16 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 14%
Small Cap (rank 785 of 912)
Percentile RankTransMedics Group, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OCS Heart System | heart transplantation | — | 2021-11-04 | OCS DCD arm survival: 95%; DBD Control arm survival: 89%; adjusted OCS survival: 94%; adjusted Control survival: 90%; utilization rate: 89% Read More | TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with... Read More | |
OCS Heart System | heart transplantation | — | 2021-11-04 | OCS DCD arm survival: 95%; DBD Control arm survival: 89%; adjusted OCS survival: 94%; adjusted Control survival: 90%; utilization rate: 89% Read More | TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with... Read More | |
OCS Heart System | heart transplantation | — | 2021-11-04 | OCS DCD arm survival: 95%; DBD Control arm survival: 89%; adjusted OCS survival: 94%; adjusted Control survival: 90%; utilization rate: 89% Read More | TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TMDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TMDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TMDXTransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
TransMedics Group has completed a strategic investment in PAD Aviation, a German private aviation operator, to establish a dedicated organ transplantation logistics network across Europe. This partnership aims to enhance the utilization of donor organs and replicate the successful OCS NOP model from the U.S. in the European market. The investment is seen as a significant step towards improving transplant activities within the EU.
Read more →TMDXTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (Nasdaq: TMDX) announced the granting of non-qualified stock options and restricted stock units as inducements for new employees. On May 19, 2026, a total of 37,367 stock options and 24,848 restricted stock units were awarded to 14 employees, including Senior Vice President Matthew S. Forsyth. These grants, approved by the Compensation Committee, are in line with Nasdaq Listing Rule 5635(c)(4) and are designed to enhance employee retention through a vesting schedule. TransMedics focuses on transforming organ transplant therapy using innovative technologies.
Read more →TMDXTransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics Group, Inc. will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The presentation will be led by the management team and is scheduled for 2:20 p.m. ET. A live and archived webcast will be available on their investor website, showcasing their advancements in organ transplant therapy.
Read more →TMDXTransMedics Reports First Quarter 2026 Financial Results
TransMedics Group, Inc. reported a 21% increase in total revenue for Q1 2026, reaching $173.9 million. The company achieved a net income of $7.3 million, although operating income fell by 52% compared to the previous year. TransMedics is focused on expanding its organ transplant logistics and has reiterated its revenue guidance for the year. The company also hosted a symposium to promote its new organ preservation technology.
Read more →TMDXTransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has entered a definitive agreement to invest in PAD Aviation, a private aviation operator in Germany. This strategic investment aims to establish a dedicated organ transplantation air logistics network across Europe, replicating their successful U.S. model. TransMedics intends to enhance patient access to donor organs and improve transplant volumes within the EU. However, the transaction is contingent upon meeting specific closing and regulatory conditions, and risks associated with the integration of PAD Aviation and potential operational disruptions are acknowledged.
Read more →TMDXTransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced an update on its clinical programs at the ISHLT 2026 Annual Meeting, introducing the Controlled Hypothermic Organ Preservation System (CHOPS). This new device aims to facilitate enrollment in the control arms of key clinical trials assessing heart and lung transplant methods. CHOPS is designed to provide stable cold storage for donor organs, differing from existing techniques. FDA has approved the IDE for these clinical trials, positioning TransMedics to strengthen its evidence base for organ transplant therapy.
Read more →TMDXTransMedics to Report First Quarter 2026 Financial Results on May 5, 2026 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026, after market close. This report will be accompanied by a conference call at 4:30 p.m. ET. The company's ongoing efforts in organ transplant therapy continue to show promise, as it focuses on improving the quality and viability of donor organs. TransMedics is based in Andover, Massachusetts and is noted for its advancements in portable organ preservation technologies.
Read more →TMDX▲ +7.9%on this news
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Group, Inc. announced the release of a $103.3 million tax valuation allowance, leading to an $83.8 million net income tax benefit for Q4 2025. This decision reflects the company's confidence in utilizing deferred tax assets due to anticipated future income. The effective tax rate for 2025 was significantly impacted by this release, resulting in a notable difference from the standard rate.
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
TransMedics Group, Inc. reported strong financial results for Q4 and full year 2025, with a 32% revenue increase in Q4 and a net income of $105.4 million. The company anticipates continued growth in 2026, projecting revenues between $727 million and $757 million. Strategic initiatives are planned to enhance organ transplant therapy adoption and expand operations in Europe.
Read more →TMDXTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced the granting of non-qualified stock options and restricted stock units to 14 employees as inducements for their employment. This includes significant grants to the Chief Commercial Officer, Giovanni Cecere. The options have a 10-year term and will vest over a period of four years, contingent on continued service.
Read more →TMDXTransMedics to Present at Upcoming March Investor Conferences TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. is set to participate in two upcoming investor conferences in March 2026. The company will engage in a fireside chat at the TD Cowen Annual Health Care Conference in Boston on March 2 and the Oppenheimer Healthcare MedTech & Services Conference on March 16. TransMedics specializes in transforming organ transplant therapy with its advanced technologies, aimed at improving organ quality and availability for transplantation.
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. announced it will release its financial results for Q4 and the full year 2025 on February 24, 2026. The management team will host a conference call at 4:30 p.m. ET to discuss the results. Investors can participate by dialing in or accessing a webcast on the company's website.
Read more →TMDXTransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics has received full FDA approval for its Investigational Device Exemption for the OCS ENHANCE Heart trial. This trial aims to support prolonged heart perfusion and demonstrate the superiority of the OCS Heart system over traditional cold storage methods. The trial is expected to include over 650 patients, making it the largest of its kind globally. The company is now focused on executing the trial and enrolling patients.
Read more →TMDXTransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of ...
TransMedics Group, Inc. has announced its plans to establish a new global headquarters at Assembly Innovation Park in Somerville, Massachusetts, with an anticipated relocation scheduled for January 2028. This move aligns with the company’s strategy to enhance its operational capabilities and ability to attract talent within the thriving life sciences ecosystem of Boston. In addition to the headquarters, TransMedics is acquiring adjacent land for campus development, which is supported by a performance-based incentive package from the Massachusetts Life Sciences Center. The initiative is expected to create up to 600 new jobs, significantly contributing to the local economy.
Read more →TMDXTransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TransMedics Group, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's advancements in organ transplant therapy for patients with end-stage organ failure. A live webcast of the event will be available on their investor website.
Read more →TMDX▲ +14%on this news
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
TransMedics Group, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The management team will engage in a fireside chat at 9:30 a.m. ET. A live and archived webcast will be available on their investor website, highlighting their advancements in organ transplant therapy.
Read more →TMDXTransMedics Reports Third Quarter 2025 Financial Results
TransMedics Group, Inc. reported a 32% increase in revenue for Q3 2025, reaching $143.8 million. The net income also saw a significant rise to $24.3 million. The company is optimistic about its growth trajectory, aiming for 10,000 U.S. NOP transplants by 2028. However, increased operating expenses and reliance on the OCS present challenges.
Read more →TMDXTransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced they will report their financial results for the third quarter of 2025 on October 29, 2025. The results will be released after market close, and a conference call will follow at 4:30 p.m. ET. TransMedics specializes in organ transplant therapy, particularly in improving the viability and preservation of donor organs.
Read more →TMDXTransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in ItalyUSA - EnglishUSA - English
TransMedics has partnered with Mercedes-Benz to create a dedicated organ transportation network in Italy, utilizing purpose-built V-Class vehicles. This initiative supports the deployment of TransMedics' Organ Care System technology and aims to enhance donor organ utilization. The first hubs are set to launch by the end of 2025, with a focus on improving access to transplantation services.
Read more →TMDXTransMedics to Present at Upcoming September Investor Conferences
TransMedics Group, Inc. will participate in two investor conferences in September 2025. The company will engage in a fireside chat at the Morgan Stanley Global Healthcare Conference and present at the Baird Global Healthcare Conference. These events aim to enhance investor relations and showcase TransMedics' advancements in organ transplant technology.
Read more →TMDX▲ +6.6%on this news
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
TransMedics Group, Inc. has received FDA conditional approval for its Next-Generation OCS ENHANCE Heart trial. This two-part clinical trial aims to enhance heart preservation techniques and potentially expand the eligibility of donor hearts. The trial is expected to involve over 650 patients, marking a significant milestone in organ transplant therapy.
Read more →TMDXTransMedics Reports Second Quarter 2025 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported strong financial results for Q2 2025, with total revenue of $157.4 million, marking a 38% increase compared to Q2 2024. The company achieved a net income of $34.9 million and has raised its full-year revenue guidance to a range of $585 million to $605 million. Additionally, TransMedics received conditional FDA approval to begin its Next-Gen OCS Lung trial. However, they face challenges including rising operating expenses and identified weaknesses in internal controls.
Read more →TMDXTransMedics Reports Second Quarter 2025 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported strong financial results for Q2 2025, with total revenue of $157.4 million, a 38% increase from the previous year. The company achieved a net income of $34.9 million and received FDA approval for its Next-Gen OCS Lung trial. Additionally, TransMedics raised its full-year revenue guidance to between $585 million and $605 million, reflecting confidence in its growth strategy.
Read more →TMDXTransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced that its management team will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The conference will focus on the company's advancements in organ transplant therapy for patients suffering from end-stage organ failure. TransMedics is recognized for its innovative technologies that enhance the quality and viability of donor organs prior to transplantation. Interested parties can access a live webcast of the event through the company's investor relations website.
Read more →TMDXTransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced that it will report its financial results for the second quarter of 2025 on July 30, 2025. The report will be released after market close, followed by a conference call at 4:30 p.m. ET. TransMedics specializes in organ transplant therapy, utilizing cutting-edge technology to improve organ viability and increase donor organ utilization. Investors will have access to both a live and archived webcast of the conference call on the company's website.
Read more →TMDXTransMedics to Present at Upcoming June Investor Conferences TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced its participation in two upcoming investor conferences. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025, and take part in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025. These events will highlight TransMedics' advancements in organ transplantation technologies and their impact on healthcare.
Read more →TMDXTransMedics Reports First Quarter 2025 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported impressive financial results for the first quarter of 2025, with revenues reaching $143.5 million, a 48% increase from Q1 2024. The company also reported a net income of $25.7 million and raised its full-year revenue guidance to between $565 million and $585 million. Additionally, TransMedics is set to expand its operations with the establishment of a new design center and manufacturing facility in Italy. The strong financial performance reflects the increased utilization of their Organ Care System (OCS) and logistics services, demonstrating the company's progress in the organ transplant technology field.
Read more →TMDXTransMedics Reports First Quarter 2025 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported strong financial results for Q1 2025, with total revenue of $143.5 million, a 48% increase year-over-year. The company also achieved a net income of $25.7 million, reflecting robust operational performance. Additionally, TransMedics raised its full-year revenue guidance, indicating confidence in continued growth. The company is focused on expanding its organ transplant technologies and services.
Read more →TMDXTransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced it will report its financial results for the first quarter of 2025 after market close on May 8, 2025. The management team will host a conference call at 4:30 p.m. ET to discuss these results. TransMedics is renowned for its advancements in organ transplant therapy, focusing on improving organ quality and viability assessment for transplantation.
Read more →TMDX▲ +7.8%on this news
TransMedics Group (TMDX) Financial Success Faces Legal Scrutiny Amid Allegations – Hagens Berman
TransMedics Group (TMDX) recently reported strong financial results, achieving $121.6 million in Q4 2024 revenue, a 50% increase year-over-year. However, the stock remains depressed due to serious allegations of securities fraud and other misconduct. A critical short-seller report has further fueled investor skepticism, leading to a class action lawsuit against the company. Hagens Berman is investigating potential illegal sales practices, adding to ongoing concerns about regulatory scrutiny and long-term profitability.
Read more →TMDX▲ +7.1%on this newsshared move
TransMedics Group (TMDX) Shares Down 60% From Class Period High, Class-Action Suit Pending – Hagens Berman
TransMedics Group, a medical technology company specializing in organ transplant therapy, is facing a class-action lawsuit for alleged fraudulent practices and safety issues. The suit, filed by Hagens Berman, claims that the company misled investors and engaged in improper billing practices. Significant events, including accusations from a congressman and a report by activist short seller Scorpion Capital, have exacerbated the company's valuation decline and raised concerns about its safety standards. The lead plaintiff deadline for affected investors is April 15, 2025.
Read more →TMDX▲ +7.1%on this newsshared move
TransMedics Group (NASDAQ: TMDX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors regarding business practices and safety oversight from February 28, 2023, to January 10, 2025. The lawsuit claims the company engaged in fraudulent activities, including kickbacks and coercive tactics. Following accusations from U.S. Rep. Paul Gosar and a report by Scorpion Capital, TransMedics' stock saw notable decreases. Investors are urged to act by April 15, 2025, if they wish to be appointed as lead plaintiffs.
Read more →TMDXTRANSMEDICS GROUP, INC. (NASDAQ: TMDX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds TransMedics Group, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a deadline alert for investors of TransMedics Group, Inc. regarding a class action lawsuit which alleges securities fraud. The lawsuit claims that the company and its senior officers made misrepresentations about safety practices, including hiding safety issues and employing fraudulent tactics. Investors who purchased shares between February 28, 2023, and January 10, 2025, are encouraged to discuss their legal rights. The deadline to serve as lead plaintiff is April 15, 2025.
Read more →TMDXTransMedics Group, Inc. Shareholders are Reminded of the Pending Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against TMDX
TransMedics Group, Inc. is facing a class action lawsuit for allegedly misleading investors regarding unsafe business practices between February 2023 and January 2025. Claims asserted include coercive sales tactics, overbilling hospitals, and inadequate safety oversight. Following the public release of these allegations, the company's stock price experienced a significant decline. Shareholders are urged to act quickly, as the deadline to file as lead plaintiff is April 14, 2024.
Read more →TMDXTransMedics Group (TMDX) Faces Class-Action Suit Over Alleged Fraud and Safety Lapses – Hagens Berman
TransMedics Group, Inc. faces a class-action lawsuit filed by investors claiming fraudulent practices and safety oversight failures. The lawsuit alleges that the company engaged in overbilling and coercive tactics while failing to disclose crucial safety issues. Specific incidents, including a letter from Representative Paul Gosar and a report from Scorpion Capital, further revealed these alleged misconducts, leading to a drop in the company's stock price. Hagens Berman, the firm investigating these claims, has urged affected investors to come forward.
Read more →TMDXTransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman
TransMedics Group, Inc. is currently embroiled in a class-action lawsuit alleging fraud and safety oversight failures. The lawsuit claims that the company engaged in misleading practices, including kickbacks and coercive tactics for revenue generation, while also failing to disclose critical safety issues. Recent reports from activist investors have further exacerbated the situation, leading to a drop in the company's stock price. The situation poses heightened regulatory risks for TransMedics and raises concerns about its business practices and investor confidence.
Read more →TMDXTransMedics Group, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – TMDX
TransMedics Group, Inc. is facing a class action lawsuit for securities law violations, with allegations spanning from fraudulent overbilling to unsafe business practices. The suit claims the company misled investors with materially false statements from February 28, 2023, to January 10, 2025. Shareholders are urged to register for participation in the legal proceedings, including the opportunity to become lead plaintiffs. The Gross Law Firm, which specializes in securing investor rights, is handling the case.
Read more →TMDXTransMedics Group (TMDX) Faces Class-Action Suit Over Alleged Fraud and Safety Lapses– Hagens Berman
TransMedics Group, Inc. (TMDX) is facing a class-action lawsuit alleging fraud and safety lapses. The lawsuit accuses the company of using improper billing techniques and concealing crucial safety issues that have exposed investors to risk. It references specific incidents, including a letter from Representative Paul Gosar and a report from activist short seller Scorpion Capital, which highlighted significant misconduct. Hagens Berman, the firm representing the plaintiffs, is investigating these claims further, emphasizing the potential implications for both investors and patients.
Read more →TMDXTransMedics Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights – TMDX
TransMedics Group, Inc. is embroiled in a class action securities lawsuit alleging fraud between February 2023 and January 2025. The lawsuit claims that the company used kickbacks, fraudulent overbilling, and coercive tactics, while also concealing safety issues. This legal action poses significant regulatory and scrutiny risks for TransMedics as it seeks to address these serious allegations. Investors affected by these circumstances are encouraged to contact Levi & Korsinsky to discuss their rights.
Read more →TMDXTransMedics Group, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – TMDX
TransMedics Group, Inc. is facing a class action securities lawsuit led by Levi & Korsinsky, LLP. The lawsuit accuses the company of severe misconduct, including allegations of using kickbacks and fraudulent practices to boost revenue while concealing safety issues. Investors who suffered losses from February 28, 2023, to January 10, 2025, are encouraged to seek compensation. The firm emphasizes that participation has no costs for affected investors.
Read more →TMDX▲ +5.8%on this newsshared move
TransMedics Group, Inc. (TMDX) Investors: April 15, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
TransMedics Group, Inc. is facing a securities class action lawsuit filed in the U.S. District Court for Massachusetts. The lawsuit pertains to alleged misconduct during a class period from February 28, 2023, to January 10, 2025, including false statements and failures to disclose critical safety issues. Investors have until April 15, 2025, to seek representation as lead plaintiffs. The law firm Kessler Topaz Meltzer & Check, LLP is acting on behalf of affected investors.
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2024 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported strong financial results for Q4 and the full year of 2024, with total revenue reaching $121.6 million for Q4 and $441.5 million for the year, representing increases of 50% and 83% respectively compared to 2023. The company also achieved a net income of $35.5 million for the year, an improvement over the previous year's loss. TransMedics has expanded its market share significantly and is poised for further growth in 2025, projecting revenue of $530 million to $552 million. Additionally, an independent review found no evidence of misconduct related to prior allegations against the company.
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2024 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported strong financial results for Q4 and full year 2024, with total revenue reaching $441.5 million, an 83% increase from 2023. The company achieved profitability with a net income of $35.5 million for the year. Additionally, TransMedics expanded its market share in organ transplant therapy and plans for continued growth in 2025.
Read more →TMDXTRANSMEDICS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against TransMedics Group, Inc. on behalf of investors who experienced substantial losses between February 28, 2023, and January 10, 2025. The lawsuit alleges violations of the Securities Exchange Act, including misleading statements about the company's practices and safety issues. Allegations include the use of kickbacks and coercive tactics, as well as accusations of overbilling hospitals and providing substandard organs. The firm invites investors to participate in the lawsuit aimed at securing relief for affected parties.
Read more →TMDXTransMedics Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 15, 2025 to Discuss Your Rights – TMDX
TransMedics Group, Inc. is facing a securities law lawsuit concerning various allegations made against the company from February 28, 2023 to January 10, 2025. Investors are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment as the suit includes claims of kickbacks, fraudulent practices, and the concealment of safety issues. The deadline for shareholders to register for this class action is April 15, 2025. The law firm aims to recover losses for investors affected by the alleged misleading statements by TransMedics.
Read more →TMDXTRANSMEDICS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX
TransMedics Group, Inc. is facing a class action lawsuit initiated by Robbins Geller Rudman & Dowd LLP, claiming the company and its executives engaged in violations of the Securities Exchange Act of 1934. The allegations include using fraudulent practices such as kickbacks and unsafe healthcare practices that led to significant losses for investors during the specified class period. The company has also been accused of misappropriating corporate resources, which resulted in a notable decline in stock price following the public disclosure of these allegations. Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit.
Read more →TMDX▲ +5.9%on this newsshared move
TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against TransMedics Group, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against TransMedics Group, Inc., alleging that the company made false and misleading statements regarding its business practices. The lawsuit claims TransMedics engaged in unethical practices, including kickbacks and coercive tactics, while failing to disclose safety issues. Investors are encouraged to join the lawsuit as lead plaintiffs. The lawsuit covers a period from February 28, 2023, to January 10, 2025, during which affected parties may seek compensation for losses incurred due to these allegations.
Read more →TMDX▲ +5.9%on this newsshared move
TransMedics Group, Inc. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against TMDX
Robbins LLP has initiated a class action against TransMedics Group, Inc. on behalf of shareholders who acquired TMDX securities between February 28, 2023, and January 10, 2025. The lawsuit centers on allegations that TransMedics misled investors about its business practices, including claims of coercive tactics, overbilling, and safety issues. Following the release of a damaging report on January 10, 2025, the stock experienced notable declines. Shareholders are encouraged to take action before the April 14, 2024 deadline to serve as lead plaintiffs in the case.
Read more →TMDX▲ +5.9%on this newsshared move
TRANSMEDICS GROUP, INC. (NASDAQ: TMDX) INVESTOR ALERT: Investors With Large Losses in TransMedics Group, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
TransMedics Group, Inc. is facing a securities class action lawsuit filed by shareholders who acquired the company's securities between February 28, 2023, and January 10, 2025. The lawsuit claims that the company misrepresented its safety practices and hid critical safety issues. Additionally, it alleges that TransMedics engaged in illegal activities such as kickbacks and fraudulent billing to enhance revenue. Shareholders interested in participating in the lawsuit must act before April 15, 2025.
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced that it will release its financial results for the fourth quarter and full year 2024 on February 27, 2025. A conference call will follow the release, allowing investors to engage with the company's management. TransMedics specializes in advancing organ transplant technologies, aiming to improve the quality and availability of organs for transplantation.
Read more →TMDXTransMedics Group, Inc. Announcement: If You Have Suffered Losses in TransMedics Group, Inc. (NASDAQ: TMDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims for shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) due to allegations of misleading business information. A report from Scorpion Capital accused TransMedics of operating under a severely flawed business model that exploits vulnerable patients. Following these serious allegations, TMDX experienced significant stock price declines. The law firm encourages affected investors to participate in a class action for possible compensation.
Read more →TMDXTRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating TransMedics Group, Inc. regarding potential violations of federal securities laws on behalf of its stockholders. The investigation follows a report from Scorpion Capital alleging that TransMedics is engaged in serious fraudulent practices, particularly in relation to the treatment of terminally ill patients. The firm encourages affected investors to reach out to discuss their rights and possible claims.
Read more →TMDXTransMedics Group, Inc. Investors: Company Investigated by the Portnoy Law Firm
TransMedics Group, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud. The investigation stems from a report by Scorpion Capital, which accuses the company of significant fraudulent activities, particularly impacting vulnerable terminally ill patients who receive unethical organ donations. The Portnoy Law Firm is reaching out to investors who may have lost money to discuss their legal options and the possibility of filing a class action lawsuit. This situation raises serious concerns about corporate governance and patient safety in the healthcare sector.
Read more →TMDX▼ -6.9%on this newsshared move
TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has responded to a report from Scorpion Capital, which the company claims contains inaccurate and misleading information. They assert that the report aims to manipulate the market for financial benefits and misrepresents their commitment to organ transplantation innovation. Despite these allegations, TransMedics remains focused on growth, including the launch of their next-gen OCS Heart and OCS Lung programs in 2025. The company is also consulting with legal advisors to explore options regarding the claims made against them.
Read more →TMDXTransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will showcase the company's advancements in organ transplant therapy, particularly in addressing end-stage lung, heart, and liver failure. A live webcast will be available for investors, emphasizing the company's commitment to increasing organ viability and utilization. TransMedics is recognized as a leader in the portable extracorporeal warm perfusion technology.
Read more →TMDXTransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has appointed Gerardo Hernandez as Chief Financial Officer, effective December 2, 2024. Hernandez brings over 25 years of experience in finance, having previously worked at Alnylam Pharmaceuticals and Shire. The company also updated its 2024 financial outlook, projecting revenue growth of 77% to 79% compared to the previous year.
Read more →TMDXTransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook Andover, Mass.
TransMedics Group, Inc. has appointed Gerardo Hernandez as Chief Financial Officer, effective December 2, 2024, succeeding Stephen Gordon. Hernandez brings over 25 years of financial expertise, having previously worked at Alnylam Pharmaceuticals and Shire, where he contributed to substantial growth and integration efforts during a major acquisition. The company also updated its financial outlook for 2024, projecting significant revenue growth of 77% to 79% compared to the previous year. TransMedics plans to discuss these developments further at upcoming investor conferences in December 2024 and January 2025.
Read more →TMDXTransMedics to Host Investor & Analyst Day on December 10, 2024 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (TMDX) announced it will hold an Investor & Analyst Day on December 10, 2024, in New York City. The company's leadership will present their growth strategy, clinical pipeline, and operational insights. The event will feature a live webcast, but in-person attendance requires prior registration. TransMedics is recognized for its advancements in organ transplant therapy, especially for end-stage heart, lung, and liver failure patients.
Read more →TMDXTransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event is scheduled for December 3, 2024, where members of the management team will engage in a fireside chat. The company is recognized for its pioneering role in transforming organ transplant therapy. Investors can access a live and archived webcast of the discussion through TransMedics' website.
Read more →TMDXTransMedics Reports Third Quarter 2024 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported strong financial results for Q3 2024, with total revenue reaching $108.8 million, a 64% increase from the previous year. The company achieved a net income of $4.2 million, contrasting sharply with a loss in the same quarter last year. Despite a decrease in gross margin, TransMedics is optimistic about its growth trajectory and aims for significant expansion in organ transplant cases by 2028.
Read more →TMDXTransMedics Reports Third Quarter 2024 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported financial results for the third quarter of 2024, revealing a total revenue of $108.8 million, a 64% increase from the same quarter in 2023. The company also achieved net income of $4.2 million, a substantial turnaround from a net loss in the prior year. However, gross margin has decreased, reflecting a shift to service revenue. Looking forward, TransMedics continues to project significant growth, aiming for $425 million to $445 million in revenue for the full year.
Read more →TMDXTransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced that it will release its third quarter 2024 financial results on October 28, 2024. A conference call will follow the release at 4:30 p.m. ET to discuss the results. The company is known for its advancements in organ transplant technology, particularly for end-stage heart, lung, and liver failure. This financial update indicates continued progress and operations within the company.
Read more →TMDXTransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference, set for September 4, 2024. During the event, management will engage in a fireside chat to discuss the company's innovations in organ transplant therapy. TransMedics specializes in portable extracorporeal warm perfusion technology to enhance organ viability and increase the use of donor organs. A live and archived webcast of the session will be accessible on their investor relations website.
Read more →TMDXTransMedics Reports Second Quarter 2024 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported strong financial results for the second quarter of 2024, highlighting a total revenue of $114.3 million, a 118% increase from the same period last year. The company achieved a net income of $12.2 million compared to a net loss in the prior year, marking a significant turnaround. Additionally, TransMedics raised its revenue outlook for the full year 2024, anticipating revenue between $425 million and $445 million. The growth was attributed to the increasing utilization of the Organ Care System (OCS) and expanding logistics services.
Read more →TMDXTransMedics Reports Second Quarter 2024 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported a strong financial performance for Q2 2024, with total revenue reaching $114.3 million, marking a 118% increase year-over-year. The company also achieved a net income of $12.2 million, contrasting with a loss in the same quarter last year. TransMedics is optimistic about future growth, raising its revenue guidance for the year. However, the gross margin has decreased, and operating expenses have increased due to higher investments in research and development.
Read more →TMDXTransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (Nasdaq: TMDX) announced its upcoming presentation at the Canaccord Genuity 44th Annual Growth Conference scheduled for August 13, 2024. The management team will discuss the company's advancements in organ transplant therapy. TransMedics specializes in improving organ preservation and assessment for transplantation purposes. A live webcast of the presentation will be made available for interested parties.
Read more →TMDXTransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced it will release its financial results for the second quarter of 2024 on July 31, 2024, after market hours. The announcement includes a scheduled conference call with the management team to discuss the results, which will be accessible to investors. TransMedics is focused on transforming organ transplantation therapies for patients facing organ failure and is recognized for its advancements in this field.
Read more →TMDXTransMedics Reports First Quarter 2024 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported a strong financial performance for Q1 2024, with net revenue of $96.9 million, marking a 133% increase from the previous year. The company also achieved a net income of $12.2 million, a significant turnaround from a loss in the same quarter last year. TransMedics raised its full-year revenue guidance, reflecting optimism about continued growth driven by its Organ Care System utilization.
Read more →TMDXTransMedics Reports First Quarter 2024 Financial Results Andover, Mass. –
TransMedics reported strong financial results for the first quarter of 2024, with net revenue increasing by 133% year-over-year to $96.9 million and achieving net income of $12.2 million. The company raised its full-year revenue guidance to a range of $390 million to $400 million. However, gross margins decreased to 62%, attributed to a larger share of service revenue, while operating expenses rose significantly due to increased investments in research and development. Overall, the results highlight TransMedics' ongoing growth and commitment to enhancing organ transplant therapies.
Read more →TMDXTransMedics to Report First Quarter 2024 Financial Results on April 30, 2024 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced it will release its financial results for the first quarter of 2024 on April 30, 2024, after market close. The management team will host a conference call to discuss the results at 4:30 p.m. ET the same day. The call can be accessed by domestic and international investors. TransMedics focuses on improving organ transplant therapies through innovative technologies.
Read more →TMDX▲ +14.1%on this newsshared move
TransMedics Group Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation on behalf of investors who lost money on TransMedics Group, Inc. (NASDAQ: TMDX) stock. This move follows a significant drop in the company's shares, which fell over 9% after reports of a federal investigation and allegations of misappropriation of resources. Investors are encouraged to contact the firm for a complimentary evaluation of their options to recover losses. The situation poses risks for TransMedics amid growing legal scrutiny.
Read more →TMDX▼ -6.5%on this newsshared move
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported a strong financial performance for Q4 and full year 2023, achieving a 159% increase in revenue year-over-year. The company generated a net income of $4 million in Q4, marking a significant turnaround from losses in the previous year. Despite increased operating expenses and a decrease in gross margin, the launch of new services and growth in transplant volumes were notable highlights.
Read more →TMDX▼ -6.5%on this newsshared move
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported a remarkable 159% revenue growth for both Q4 and the full year of 2023, alongside a net income of $4.0 million in Q4. The company attributes this success to the increased utilization of its Organ Care System (OCS) technology and the launch of new logistics services. However, operating expenses rose significantly, leading to a net loss for the full year, highlighting the ongoing challenges they face despite positive financial trends. TransMedics expects to continue this growth trajectory with a revenue forecast of $360 to $370 million for 2024.
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (TMDX) announced it will release its fourth quarter and full year 2023 financial results on February 26, 2024. A conference call will follow the release, allowing investors to engage directly with management. The company specializes in transforming organ transplant therapy through its advanced technologies for organ preservation and viability assessment.
Read more →TMDXTransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The management team is expected to present the company's advancements in organ transplant therapy, particularly for end-stage heart, lung, and liver failure. This conference is an important platform for healthcare companies to connect with investors and stakeholders, potentially leading to increased visibility and support for TransMedics’ innovations in portable organ perfusion technology.
Read more →TMDX▲ +8.7%on this news
TransMedics to Present at the Piper Sandler 35th Annual Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced its participation in the Piper Sandler 35th Annual Healthcare Conference, scheduled for November 28, 2023. The management team will engage in a fireside chat at 2:30 p.m. ET. The event aims to spotlight TransMedics' innovative technologies aimed at improving organ transplant therapies for patients with end-stage organ failure. The conference is a significant occasion for the company to showcase its leadership in the transplantation market.
Read more →TMDX▼ -5.7%on this news· ran to +43% by day 1
TransMedics Reports Third Quarter 2023 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported impressive third quarter 2023 financial results, with net revenue reaching $66.4 million, a 159% increase from the previous year. The company successfully closed the acquisition of Summit Aviation, contributing to the revenue and enhancing its service offerings in organ transplant therapy. However, the company's operating expenses surged to $69 million, resulting in a net loss of $25.4 million, attributed largely to non-recurring acquisition-related costs. Despite these challenges, TransMedics is optimistic about future growth, updating its full-year revenue guidance to a range of $222-$230 million.
Read more →TMDX▼ -5.7%on this news· ran to +43% by day 1
TransMedics Reports Third Quarter 2023 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported a significant increase in net revenue for Q3 2023, reaching $66.4 million, a 159% rise from the previous year. The company successfully acquired Summit Aviation, contributing to its growth strategy. However, it also faced a net loss of $25.4 million, attributed to increased operating expenses and transition costs. Management remains optimistic about future growth prospects.
Read more →TMDXTransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. is set to release its third quarter 2023 financial results on November 6, 2023, after market close. The company, known for its innovations in organ transplant therapy, will also host a conference call at 4:30 p.m. ET. Investors can join the call through dedicated phone lines or via a webcast available on TransMedics' website. This report follows the company's mission to enhance organ viability and utilization in transplantation for patients with severe organ failure.
Read more →TMDXTransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced its participation in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference, scheduled for September 11, 2023. During the event, members of the management team will engage in a fireside chat to discuss their advancements in organ transplant therapies. The company specializes in technologies designed to enhance organ quality and viability, addressing the needs in the transplantation space for patients with end-stage organ failure. A live and archived webcast of the chat will be available on their investor relations website.
Read more →TMDXTransMedics Completes Acquisition of Summit Aviation Andover, Mass.
TransMedics Group, Inc. has completed the acquisition of Summit Aviation, aiming to create TransMedics Aviation, which will serve as a dedicated air logistics provider for organ transplantation. This strategic move is part of the company's plan to enhance the National OCS Program, enabling better reach and logistics for organ transplants across the U.S. The acquisition introduces important challenges, including risks associated with integration and management focus. Despite these risks, the move is expected to contribute positively to the company's operational capabilities in the medical field.
Read more →TMDXTransMedics Completes Acquisition of Summit Aviation TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has completed its acquisition of Summit Aviation, establishing TransMedics Aviation as a dedicated air logistics provider for organ transplantation in the U.S. This strategic move aims to enhance the National OCS Program's reach. CEO Waleed Hassanein expressed optimism about the acquisition's potential to improve organ transplant logistics.
Read more →TMDXTransMedics Reports Second Quarter 2023 Financial Results Andover, Mass. –
TransMedics Group, Inc. has reported a strong financial performance for the second quarter of 2023, with net revenue reaching $52.5 million, marking a 156% increase from the prior year. The company has also expanded its product portfolio through acquisitions and has received CE marking for one of its key products. However, operating expenses have significantly increased, and the company still faces challenges such as a net loss and dependency on major customers. TransMedics is optimistic about its growth trajectory and has updated its revenue guidance for 2023 to indicate continued growth.
Read more →TMDXTransMedics Reports Second Quarter 2023 Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. reported a strong financial performance for Q2 2023, with net revenue reaching $52.5 million, a 156% increase year-over-year. The company has signed an agreement to acquire Summit Aviation and has received CE mark approval for its OCS Liver technology. Despite a net loss of $1 million, the company is optimistic about future growth, updating its revenue guidance to $180-$190 million for the year.
Read more →TMDX▼ -6.2%on this news· ran to -27% by day 3shared move
TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced its acquisition of proprietary technologies from Bridge to Life, including the Ex-Vivo Organ Support System (EVOSS) and LifeCradle Heart Preservation Transport System. This move is aimed at expanding TransMedics' product offerings and enhancing its position in the organ transplantation field. The company's CEO highlighted the strategic opportunities arising from these technologies, although the acquisition is accompanied by risks related to development and integration. Overall, the acquisition reflects TransMedics' commitment to advancing organ transplant therapies.
Read more →TMDXTransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced a definitive agreement to acquire Summit Aviation, aiming to create the first national provider of air logistics focused on organ transplantation in the U.S. The acquisition is expected to close in the third quarter of 2023, pending certain closing conditions. Ben Walton, Summit's founder, will join TransMedics as VP of Aviation Services. The deal aims to enhance TransMedics' national transplant aviation capabilities and expand the reach of the National OCS Program.
Read more →TMDXTransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has appointed Anil Ranganath as the Senior Vice President, General Counsel, and Corporate Secretary. Ranganath, who brings over 15 years of experience in the life sciences industry, expressed excitement about joining the company during a crucial growth phase. His background includes significant roles at Waters Corporation and Brown Rudnick LLP, providing him with insight valuable to TransMedics' strategic objectives. This leadership change aligns with TransMedics' mission of advancing organ transplantation technology.
Read more →TMDXTransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (TMDX) has announced that its management team will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The presentation will take place at 5:00 p.m. Eastern Standard Time at the InterContinental Boston Hotel. TransMedics is recognized for its advancements in organ transplant therapy, focusing on enhancing the quality and viability of donor organs.
Read more →TMDXTransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. (Nasdaq: TMDX) announced plans to release its second quarter 2023 financial results on August 3, 2023. The management team will host a conference call at 4:30 p.m. ET to discuss the financial outcomes. TransMedics specializes in portable extracorporeal warm perfusion technology for organ transplantation and aims to improve organ quality and viability assessments for patients with end-stage organ failure.
Read more →TMDXTransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has priced $400 million in convertible senior notes due 2028, up from an earlier planned $300 million. The company expects to use the proceeds for expanding its logistics network and other corporate purposes, with net proceeds estimated at $387.2 million after expenses. Additionally, the notes are convertible to stock and will bear a cash interest rate of 1.50%. Capped call transactions are being employed to mitigate potential dilution upon conversion of the notes.
Read more →TMDXTransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced a proposed offering of $300 million in convertible senior notes due in 2028. The proceeds from this offering will be partly used to expand its logistics network through partnerships or acquisitions and to cover the costs of certain capped call transactions. The notes aim to enhance company liquidity while potentially reducing the dilution risk for existing shareholders. However, the offering's success rest on market conditions and other uncertainties that could affect the anticipated terms.
Read more →TMDXTransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has released its inaugural Environmental, Social & Governance (ESG) report, reflecting its commitment to sustainable and responsible organ transplantation. CEO Waleed Hassanein emphasized the importance of improving clinical outcomes for organ transplant patients while adhering to ESG principles. The report aligns with the Sustainability Accounting Standards Board (SASB) standards, showcasing TransMedics' dedication to transparency and accountability in their practices. The company continues to innovate in organ preservation and viability assessment, potentially increasing organ utilization.
Read more →TMDXTransMedics Reports First Quarter 2023 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported strong financial results for the first quarter of 2023, with a net revenue of $41.6 million, representing a 162% increase year-over-year. The growth is primarily attributed to the adoption of the National OCS Program. However, while revenues soared, operating expenses also rose significantly to $30.9 million. The company updated its full-year revenue guidance to between $160 million and $170 million, indicating continued optimism despite the challenges.
Read more →TMDX▲ +5.1%on this news· ran to +19% by day 3
TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has announced it will release its financial results for the first quarter of 2023 after market close on May 1, 2023. A conference call will follow, allowing investors to engage directly with the management team. The company is recognized as a leader in portable warm perfusion for organ transplants, focusing on improving organ quality and viability. This announcement highlights TransMedics' ongoing efforts in the organ transplant sector.
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2022 Financial Results Andover, Mass. –
TransMedics Group, Inc. reported significant financial growth for the fourth quarter and full year of 2022, with revenues up 225% and 209% year-over-year, respectively. The company attributed this growth primarily to its OCS product line and expansion of its National OCS Program. Despite the impressive revenue increases, operating expenses also rose sharply, resulting in ongoing net losses. Looking ahead, TransMedics expects revenues for 2023 to grow by 48% to 55%, indicating a continued positive growth trajectory.
Read more →TMDXTransMedics to Present at Upcoming March Investor Conferences
TransMedics Group, Inc. will participate in two investor conferences in March 2023. The company will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference and present virtually at the Oppenheimer 33rd Annual Healthcare Conference. These events aim to enhance investor awareness of TransMedics' advancements in organ transplant therapy.
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. announced it will release its financial results for the fourth quarter and full year of 2022 on February 22, 2023. The release will be followed by a conference call at 4:30 p.m. ET for investors. TransMedics specializes in transforming organ transplant therapy, focusing on improving the quality and viability assessment of donor organs. The company aims to enhance organ utilization for patients with end-stage heart, lung, and liver failure.
Read more →TMDXTransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
TransMedics Group, Inc. has appointed Nick Corcoran as the Senior Vice President of Supply Chain and Operations, a move aimed at enhancing the company's operational capabilities. With over 20 years of supply chain and operations experience, Corcoran is expected to lead efforts to scale and improve efficiency in response to the growing demand for OCS products. His expertise from previous roles at Stryker Corporation positions him well to support TransMedics' growth strategy in the organ transplant market. This appointment comes as TransMedics continues to innovate and expand its service offerings.
Read more →TMDXTransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manag
Read more →TMDXTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ( TransMedics ) (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Nov. 7, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 2, 2022 ,
Read more →TMDXTransMedics Reports Third Quarter 2022 Financial Results Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $80 million t
TransMedics Reports Third Quarter 2022 Financial Results Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $80 million to $85 million Andover, Mass. - November 3, 2022 - TransMe
Read more →TMDXTransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release finan
Read more →TMDXTransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manag
Read more →TMDXTransMedics Announces Upsize and Pricing of Public Offering of Common Stock TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the upsize and pricing of a
Read more →TMDX▲ +5.6%on this news· ran to +24% by day 3shared move
TransMedics Announces Proposed Public Offering of Common Stock TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Aug. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a propo
Read more →TMDXTransMedics Reports Second Quarter 2022 Financial Results Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million Andover, Mass.
TransMedics Reports Second Quarter 2022 Financial Results Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million Andover, Mass. - August 1, 2022 - TransMedics Group, Inc. ("TransMedics") (Nasdaq:
Read more →TMDXTransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manag
Read more →TMDXTransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release finan
Read more →TMDXTransMedics Reports First Quarter 2022 Financial Results Andover, Mass.
TransMedics Reports First Quarter 2022 Financial Results Andover, Mass. - May 3, 2022 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure,
Read more →TMDX▲ +6.5%on this newsshared move
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , April 28, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and D
Read more →TMDXTransMedics to Report First Quarter 2022 Financial Results on May 3, 2022 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release fina
Read more →TMDXTransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that new clinical data f
Read more →TMDXTransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the manag
Read more →TMDX▼ -5.3%on this news· ran to +39% by day 3shared move
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results Andover, Mass.
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results Andover, Mass. - February 23, 2022 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart
Read more →TMDX▼ -7.6%on this news· ran to +19% by day 3shared move
TransMedics to Present at the Cowen 42nd Annual Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Feb. 22, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the manag
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financ
Read more →TMDX▼ -6.6%on this news
TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the publication of OCS™ Li
Read more →TMDXTransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the manag
Read more →TMDXTransMedics Reports Third Quarter 2021 Financial Results TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the q
Read more →TMDXTransMedics Group, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)
TransMedics Reports Third Quarter 2021 Financial Results Andover, Mass. - November 9, 2021 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver fail
Read more →TMDX▲ +6.7%on this newsshared move
TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced positive topline results f
Read more →TMDX▲ +6.7%on this newsshared move
TransMedics to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manage
Read more →TMDXTransMedics to Report Third Quarter 2021 Financial Results on November 9, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Oct. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release finan
Read more →TMDXTransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Sept. 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and D
Read more →TMDXTransMedics, Inc Press Release |
Inc Press Release | Sept 29, 2021 TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Andover, Mass. September 29, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is trans
Read more →TMDXTransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplantation in the U.S. TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Dr
Read more →TMDX▲ +7.6%on this news
TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manag
Read more →TMDXTransMedics Reports Second Quarter 2021 Financial Results TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the q
Read more →TMDXTransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced U.S. Food and Drug Admini
Read more →TMDXTransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the manag
Read more →TMDXTransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release finan
Read more →TMDXTransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System Panel votes unanimously in support of the OCS Liver System s safety and effectiveness Andover, Mass.
TransMedics Announces Positive FDA Advisory Committee Vote for the votes unanimously in support of the OCS Liver System s safety and effectiveness Andover, Mass. July 14, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transfor
Read more →TMDXTransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted tr
Read more →TMDXTransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Dru
Read more →TMDXTransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021) TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , June 8, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the complete results of the
Read more →TMDXTransMedics Reports First Quarter 2021 Financial Results Andover, Mass.
TransMedics Reports First Quarter 2021 Financial Results Andover, Mass. - May 4, 2021 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure,
Read more →TMDXTransMedics to Report First Quarter 2021 Financial Results on May 4, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release fina
Read more →TMDXTransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System Panel votes 12 to 5 that benefits of OCS Heart System outweigh risks Andover, Mass.
TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System Panel votes 12 to 5 that benefits of OCS Heart System outweigh risks Andover, Mass. April 6, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transf
Read more →TMDXTransMedics Appoints Stephanie Lovell to Board of Directors TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , March 24, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Steph
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2020 Financial Results TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , March 2, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the q
Read more →TMDXTransMedics Group, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) December 31
TransMedics Reports Fourth Quarter and Full Year 2020 Financial Results Andover, Mass. - March 2, 2021 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and
Read more →TMDXTransMedics Announces Scheduling of OCS Heart FDA Advisory Committee Meeting TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , March 1, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA's Office of H
Read more →TMDXTransMedics to Present at the Cowen 41st Annual Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the manag
Read more →TMDXTransMedics to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release finan
Read more →TMDXTransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the manag
Read more →TMDXTransMedics Appoints Merilee Raines to Board of Directors TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass. , Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Merile
Read more →TMDXTransMedics Reports Third Quarter 2020 Financial Results Andover, Mass.
TransMedics Reports Third Quarter 2020 Financial Results Andover, Mass. - November 4, 2020 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failu
Read more →TMDXTransMedics to Participate in Upcoming Virtual Investor Conferences TransMedics Group, Inc. ( TransMedics ) (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...
ANDOVER, Mass . , Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of the manag
Read more →TMDXTransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting
TransMedics Group, Inc. announced the FDA has temporarily postponed the Advisory Committee meeting for its OCS Heart premarket approval application, originally set for October 7, 2020. This delay allows the FDA to review additional data from the OCS Heart EXPAND trial. Despite the setback, TransMedics expresses confidence in the data supporting the OCS Heart's approval.
Read more →TMDXTransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference
TransMedics Group, Inc. will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020. The management team will engage in a fireside chat to discuss the company's advancements in organ transplant therapy. A live and archived webcast will be available on their website.
Read more →TMDXTransMedics Reports Second Quarter 2020 Financial Results
TransMedics Group, Inc. reported a 40% decrease in net revenue for Q2 2020, totaling $3.4 million, attributed to fewer organ transplant procedures during the COVID-19 pandemic. Despite this, the company achieved significant milestones and aims to have its OCS products approved in 2021. The net loss for the quarter was $8.5 million, with cash reserves at $139.4 million.
Read more →TMDXTransMedics to Present at the Canaccord 40th Annual Growth Conference
TransMedics Group, Inc. will present at the Canaccord 40th Annual Growth Conference on August 13, 2020. The virtual event aims to showcase the company's advancements in organ transplant technology. A live and archived webcast will be available on their website for interested investors.
Read more →TMDXTransMedics Announces Pricing of Public Offering of Common Stock
TransMedics Group, Inc. has announced the pricing of a public offering of 5 million shares at $14.00 each, aiming to raise $70 million. The offering is set to close on May 29, 2020, pending customary conditions. J.P. Morgan and Morgan Stanley are leading the offering, with an option for underwriters to purchase additional shares.
Read more →TMDXTransMedics Announces Proposed Public Offering of Common Stock
TransMedics Group, Inc. has announced a proposed public offering of $60 million in common stock, with all shares being offered by the company. J.P. Morgan and Morgan Stanley are leading the offering, which includes a 30-day option for underwriters to purchase additional shares. The SEC has declared the related registration statement effective. Investors are advised to review the prospectus for detailed information.
Read more →TMDXTransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial
TransMedics Group, Inc. announced positive results from its U.S. Pivotal OCS Liver PROTECT Trial, meeting both primary and secondary endpoints. The trial demonstrated a significantly lower incidence of early allograft dysfunction and ischemic cholangiopathy compared to control. With a high patient survival rate and a 98.1% utilization rate of donor livers, the results suggest transformative potential for liver transplantation.
Read more →TMDXTransMedics Reports First Quarter 2020 Financial Results Andover, Mass.
TransMedics Reports First Quarter 2020 Financial Results Andover, Mass. May 06, 2020 (GLOBE NEWSWIRE) TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and l
Read more →TMDXTransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020 Andover, Mass.
TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020 Andover, Mass. April 13, 2020 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for
Read more →TMDXTransMedics Reports Fourth Quarter and Full Year 2019 Financial Results Andover, Mass.
TransMedics Reports Fourth Quarter and Full Year 2019 Financial Results Andover, Mass. - March 2, 2020 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and
Read more →TMDXDBD Donors Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including st
DBD Donors Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our results of operations, commercial opport
Read more →TMDXTransMedics Reports Third Quarter 2019 Financial Results Andover, Mass.
TransMedics Reports Third Quarter 2019 Financial Results Andover, Mass. - November 6, 2019 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failu
Read more →TMDXTransMedics Reports Second Quarter 2019 Financial Results Andover, Mass.
TransMedics Reports Second Quarter 2019 Financial Results Andover, Mass. - August 7, 2019 - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failur
Read more →TMDXTransMedics Reports First Quarter 2019 Financial Results Andover, Mass.
TransMedics Reports First Quarter 2019 Financial Results Andover, Mass. June 11, 2019 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, to
Read more →TMDXTransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage Andov
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage Andover, Mass. June 3, 2019 TransMedics Group, Inc. ( TransMed
Read more →Competitive Position
How TMDX ranks across every disease it competes inCompetitive Position is a premium feature
See how TMDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial